Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enanta Pharmaceuticals, Inc.

https://www.enanta.com/home/default.aspx

Latest From Enanta Pharmaceuticals, Inc.

Metacrine’s Shift Means Further Attrition In FXR Agonist Class For NASH

Metacrine halts development of its FXR agonist compounds in NASH and turn its focus to inflammatory bowel disease. Firm plans Phase II ulcerative colitis study in 2022 with MET642.

Business Strategies Drug Approval Standards

Terns Says Phase IIa Data Show Superior NASH Safety Profile In FXR Class

TERN-101 showed a superior safety and tolerability profile for lipid levels and pruritis compared to other FXR agonists in a mid-stage study. Terns is now looking to a NASH combo study with its THR beta agonist.

Clinical Trials Business Strategies

Galaxy Gets $18M To Advance Centauri Pulsed Field Ablation System

ATP, a venture capital firm focused on life sciences, is providing the series A round to help Galaxy complete European and Canadian trials of its Centauri pulsed field ablation technology to treat atrial fibrillation.

Financing Clinical Trials

Medtronic, Farapulse Advance Pulsed Field Ablation With US Trials

Two pivotal US trials of pulsed field ablation systems began in early March. Farapulse is sponsoring the ADVENT randomized trial of the Farapulse PFA system and Medtronic launched the international PULSED AF trial of its PulseSelect PFA system.

Clinical Trials Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register